272 ILLINOIS STATE ACADEMY OF SCIENCE 



These findings were later confirmed by Moore of Johns 

 Hopkins (Journal A. M. A., Feb. 16, 1924). 



Following this inspiring report letters poured into our 

 state institutions from anxious relatives inquiring if this 

 new treatment could not be given to their patients, and 

 accordingly in July, 1922, arrangements were made 

 through the courtesy of Dr. Lorenz for a supply of this 

 new arsenical, not yet upon the market, which can be 

 given in very large doses — three grams each week intra- 

 venously, associated with a mercury salicylate. At the 

 same time another group of similar patients was placed 

 upon a modification of arsphenamine known as sulphar- 

 sphcnamine. It is mainly with the results obtained with 

 these two groups that this report has to do, although 

 various other modes of therapy are being tried. At this 

 same time 60 patients are under intensive treatment at 

 the Elgin State Hospital with these and other remedies, 

 notably new mercurials that can be given intravenously, 

 a new arsenical allied to tryparsamid and a form of non 

 specific treatment less dangerous than malarial infection. 



We let the slides speak for themselves as to the exact 

 results obtained, and summarize them in general as fol- 

 lows : 



. Remissions thus far secured in either group do not 

 surpass the percentage that may be expected in cases 

 treated in the usual manner with arsphenamine. The im- 

 provement in physical health in the tryparsamid group 

 has been notable and many negative bloods have also 

 been obtained, but no negative Wassermann in the spinal 

 fluid as yet. 



Several cases of apparent early optic atrophy (one or 

 two of them very evident) have been found in both these 

 treated groups, though the patients in the tryparsamid 

 group were the only ones examined at the beginning of 

 treatment. 



Some of the sulpharsphenamine treated cases have also 

 made marked improvements (one remission) but 25 per 

 cent are worse than at the beginning of treatment, where- 

 as none in the tryparsamid group have apparently de- 

 teriorated. 



